2012;125:2821 3. 301. Shimada YJ, Nakra NC, Fox JT, et al. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intrave- nous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2012;109:624 8. 302. Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intra- venous administration of abciximab in patients with ST-segment eleva- tion myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Re- perfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial. Circulation. 2010;122:2709 17. 303. Thiele H, W hrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379:923 31. 304. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295:1519 30. 305. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open- label ATOLL trial. Lancet. 2011;378:693 703. 306. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-con- trolled clinical trial. Lancet. 1988;1:545 9. 307. EMERAS (Estudio Multic ntrico Estreptoquinasa Rep blicas de Am rica del Sur) Collaborative Group. Randomised trial of late throm- bolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767 72. 308. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349 60. 309. Late Assessment of Thrombolytic Efficacy (LATE) study with al- teplase 6 24 hours after onset of acute myocardial infarction. 